Evidence-based management of arrhythmogenic right ventricular cardiomyopathy in pregnancy.
Jagjit KhoslaReshma GolamariAlice CaiJamal BensonWilbert S AronowRahul JainRohit JainPublished in: Future cardiology (2020)
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic disorder resulting in fibrofatty replacement of the myocardium. Genetic mutations in genes encoding for desmosome proteins result in a ventricular myocardium prone to arrhythmias and heart failure. Although ARVC is known for a few decades, most of the outcomes in pregnancy are reported recently. Pregnancy leads to significant physiological changes with excess mechanical stress on the myocardium. All the retrospective studies suggest that pregnancy is well tolerated in these patients despite the high risk of arrhythmias and heart failure. Our review focuses on the most up-to-date evidence on the management of ARVC patients during the antepartum and postpartum period.
Keyphrases
- heart failure
- end stage renal disease
- ejection fraction
- preterm birth
- newly diagnosed
- chronic kidney disease
- left ventricular
- genome wide
- peritoneal dialysis
- prognostic factors
- type diabetes
- copy number
- cardiac resynchronization therapy
- weight loss
- transcription factor
- patient reported
- insulin resistance
- heat stress
- genome wide identification
- case control
- genome wide analysis